Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone and Simvastatin for Neurotoxicity Prophylaxis in Axi-Cel Treatment
NCT04514029Phase 1Active, not recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2020
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dexamethasone and simvastatin in neurotoxicity, sponsored by Masonic Cancer Center. Primary endpoint: Treatment Completion Rate at 30 days. Started Aug 2020; status: active, not recruiting.
02
Drugs
dexamethasonesimvastatin
03
Conditions
neurotoxicity
Beyond the preview
Go deeper on NCT04514029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514029.